Gilead Sciences ( NASDAQ:GILD ) First Quarter 2024 Results Key Financial Results Revenue: US$6.69b (up 5.3% from 1Q...
Gilead stock pared its gains Friday after beating first-quarter sales forecasts on the back of its Covid treatment, Veklury.
Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.